Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies

Coco, Régis, Plapied, Laurence, Pourcelle, Vincent, Jérôme, Christine, Brayden, David J., Schneider, Yves-Jacques, Préat, Véronique·2013·International Journal of Pharmaceutics

Abstract

For inflammatory bowel disease (IBD) treatment, local delivery of molecules loaded in nanoparticles to the inflamed colon could be a promising strategy. The aim of this study was to investigate how drug-loaded polymeric nanoparticles target the site of inflammation and to analyse the influence of different colon-specific delivery strategies. Three different polymeric nanoparticles were formulated using ovalbumin (OVA) as a model drug. pH-sensitive nanoparticles were made with Eudragit(®) S100. Mucoadhesive nanoparticles were created with trimethylchitosan (TMC). A mix of polymers, PLGA, PEG-PLGA and PEG-PCL, were used to obtain a sustained drug delivery. Furthermore, ligands targeting immune cells (i.e. mannose) or the inflamed colon (i.e. a specific peptide) were grafted on the PEG chain of PCL. Interaction of nanoparticles with the intestinal epithelium was explored using Caco-2 monolayers designed to mimic an inflamed epithelium and then visualized using confocal laser microscopy. TMC nanoparticles had the highest apparent permeability for OVA in the untreated model. However, in the inflamed model, there were no difference between TMC, PLGA-based and Eudragit(®) nanoparticles. The uptake of nanoparticles in the inflamed mouse colon was assessed in a horizontal diffusion chamber. Mannose-grafted PLGA nanoparticles showed the highest accumulation of OVA in inflamed colon. Based on these results, active targeting of macrophages and dendritic cells may be a promising approach…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2012.07.017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 47

  1. Carter, 2004, Guidelines for the management of inflammatory bowel disease in adults, Gut, 53, V1, 10.1136/gut.2004.043372 · DOI
  2. Cartiera, 2009, The uptake and intracellular fate of PLGA nanoparticles in epithelial cells, Biomaterials, 30, 2790, 10.1016/j.biomaterials.2009.01.057 · DOI · Paper page
  3. Cornaggia, 2011, Chronic idiopathic inflammatory bowel diseases: the histology report, Dig. Liver Dis., 43, S293, 10.1016/S1590-8658(11)60585-9 · DOI
  4. Damge, 2010, Poly(epsilon-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes, J. Pharm. Sci., 99, 879, 10.1002/jps.21874 · DOI
  5. des Rieux, 2005, Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium, Eur. J. Pharm. Sci., 25, 455, 10.1016/j.ejps.2005.04.015 · DOI
  6. des Rieux, 2007, An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells, Eur. J. Pharm. Sci., 30, 380, 10.1016/j.ejps.2006.12.006 · DOI
  7. des Rieux, 2007, Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium, J. Control. Release, 118, 294, 10.1016/j.jconrel.2006.12.023 · DOI
  8. El-Kamel, 2001, Preparation and evaluation of ketoprofen floating oral delivery system, Int. J. Pharm., 220, 13, 10.1016/S0378-5173(01)00574-9 · DOI
  9. Feczko, 2011, Influence of process conditions on the mean size of PLGA nanoparticles, Chem. Eng. Process. Process Intensification, 50, 846, 10.1016/j.cep.2011.05.006 · DOI
  10. Feczko, 2011, Optimization of protein encapsulation in PLGA nanoparticles, Chem. Eng. Process. Process Intensification, 50, 757, 10.1016/j.cep.2011.06.008 · DOI
  11. Fievez, 2009, Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination, Eur. J. Pharm. Biopharm., 73, 16, 10.1016/j.ejpb.2009.04.009 · DOI
  12. Fredenberg, 2011, The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—a review, Int. J. Pharm., 415, 34, 10.1016/j.ijpharm.2011.05.049 · DOI
  13. Freichels, 2012, Easy functionalization of amphiphilic poly(ethylene oxide)-b-poly(ɛ-caprolactone) copolymer micelles with unprotected sugar: synthesis and recognition by lectins, Polym. Chem., 3, 1436, 10.1039/c2py00572g · DOI
  14. Friend, 2005, New oral delivery systems for treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev., 57, 247, 10.1016/j.addr.2004.08.011 · DOI
  15. Grimpen, 2010, Advances in the management of inflammatory bowel disease, Intern. Med. J., 40, 258, 10.1111/j.1445-5994.2010.02163.x · DOI
  16. Jain, 2005, Eudragit S100 entrapped insulin microspheres for oral delivery, AAPS PharmSciTech, 6, E100, 10.1208/pt060116 · DOI
  17. Jain, 2007, Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon, J. Pharm. Pharm. Sci., 10, 86
  18. Jain, 2010, Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug, J. Control. Release, 148, 359, 10.1016/j.jconrel.2010.09.003 · DOI
  19. Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res., 18, 788, 10.1023/A:1011032328064 · DOI · Paper page
  20. Li, 2001, PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats, J. Control. Release, 71, 203, 10.1016/S0168-3659(01)00218-8 · DOI · Paper page
  21. Liboni, 2004, Mechanism of glutamine-mediated amelioration of lipopolysaccharide-induced IL-8 production in Caco-2 cells, Cytokine, 26, 57, 10.1016/j.cyto.2003.12.008 · DOI
  22. Makhlof, 2009, pH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm., 72, 1, 10.1016/j.ejpb.2008.12.013 · DOI
  23. Means, 1968, Reductive alkylation of amino groups in proteins, Biochemistry, 7, 2192, 10.1021/bi00846a023 · DOI
  24. Meissner, 2008, Alternative drug delivery approaches for the therapy of inflammatory bowel disease, J. Pharm. Sci., 97, 2878, 10.1002/jps.21216 · DOI
  25. Melgar, 2005, Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation, Am. J. Physiol. Gastrointest. Liver Physiol., 288, G1328, 10.1152/ajpgi.00467.2004 · DOI
  26. Moulari, 2008, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials, 29, 4554, 10.1016/j.biomaterials.2008.08.009 · DOI
  27. Mourya, 2009, Trimethyl chitosan and its applications in drug delivery, J. Mater. Sci. Mater. Med., 20, 1057, 10.1007/s10856-008-3659-z · DOI
  28. Osth, 2003, Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa in vitro, J. Drug Target., 11, 75, 10.1080/1061186031000093254 · DOI
  29. Plapied, 2010, Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery, Int. J. Pharm., 398, 210, 10.1016/j.ijpharm.2010.07.041 · DOI
  30. Plevy, 2011, Future therapeutic approaches for inflammatory bowel diseases, Gastroenterology, 140, 1838, 10.1053/j.gastro.2011.02.014 · DOI
  31. Pourcelle, 2009, Light induced functionalization of PCL-PEG block copolymers for the covalent immobilization of biomolecules, Biomacromolecules, 10, 966, 10.1021/bm900027r · DOI
  32. Pourcelle, 2012, Clickable PEG conjugate obtained by clip photochemistry: synthesis and characterization by quantitative 19F NMR, J. Fluorine Chem., 140, 62, 10.1016/j.jfluchem.2012.05.006 · DOI
  33. Rijcken, 2007, Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies, Biomaterials, 28, 5581, 10.1016/j.biomaterials.2007.08.047 · DOI
  34. Rogler, 2010, Gastrointestinal and liver adverse effects of drugs used for treating IBD, Best Pract. Res. Clin. Gastroenterol., 24, 157, 10.1016/j.bpg.2009.10.011 · DOI
  35. Sadeghi, 2008, Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells, Eur. J. Pharm. Biopharm., 70, 270, 10.1016/j.ejpb.2008.03.004 · DOI
  36. Sayin, 2009, TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines, Eur. J. Pharm. Sci., 38, 362, 10.1016/j.ejps.2009.08.010 · DOI
  37. Schmidt, 2010, Confocal laser endomicroscopy (CLE) reveals mucosal accumulation of PLGA-nanoparticles in ulcerous lesions of patients with inflammatory bowel diseases, Gastroenterology, 138, S-687, 10.1016/S0016-5085(10)63157-5 · DOI
  38. Shive, 1997, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5, 10.1016/S0169-409X(97)00048-3 · DOI · Paper page
  39. Slutter, 2009, Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination, J. Control. Release, 138, 113, 10.1016/j.jconrel.2009.05.011 · DOI
  40. Soni, 2006, Rat, ovine and bovine Peyer's patches mounted in horizontal diffusion chambers display sampling function, J. Control. Release, 115, 68, 10.1016/j.jconrel.2006.06.021 · DOI
  41. Stallmach, 2010, Adverse effects of biologics used for treating IBD, Best Pract. Res. Clin. Gastroenterol., 24, 167, 10.1016/j.bpg.2010.01.002 · DOI
  42. Takagi, 2007, Identification of ligands binding specifically to inflammatory intestinal mucosa using phage display, Clin. Exp. Pharmacol. Physiol., 34, 286, 10.1111/j.1440-1681.2007.04563.x · DOI
  43. Van De Walle, 2010, Inflammatory parameters in Caco-2 cells: effect of stimuli nature, concentration, combination and cell differentiation, Toxicol. In Vitro, 24, 1441, 10.1016/j.tiv.2010.04.002 · DOI
  44. Vangeyte, 2004, Self-assembly of poly(ethylene oxide)-b-poly(ɛ-caprolactone) copolymers in aqueous solution, Langmuir, 20, 8442, 10.1021/la049695y · DOI
  45. Yeh, 2011, Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening, Biomaterials, 32, 6164, 10.1016/j.biomaterials.2011.03.056 · DOI
  46. Zambito, 2006, Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport, Eur. J. Pharm. Biopharm., 64, 16, 10.1016/j.ejpb.2006.01.004 · DOI
  47. Zweers, 2004, In vitro degradation of nanoparticles prepared from polymers based on dl-lactide, glycolide and poly(ethylene oxide), J. Control. Release, 100, 347, 10.1016/j.jconrel.2004.09.008 · DOI

Cited by

Sorted by citations

See all 162

Metadata

Authors
Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D. J., Schneider, Y.-J., & Préat, V.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2013-01
Volume
440
Issue
1
Pages
3-12
ISSN
0378-5173
Cited by
162
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review